motesanib   Click here for help

GtoPdb Ligand ID: 5660

Synonyms: AMG 706 | AMG-706
PDB Ligand
Compound class: Synthetic organic
Comment: Motesanib is a pan-VEGFR inhibitor that was investigated for anti-tumourigenic efficacy.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 6
Topological polar surface area 78.94
Molecular weight 373.19
XLogP 2.99
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(c1cccnc1NCc1ccncc1)Nc1ccc2c(c1)NCC2(C)C
Isomeric SMILES O=C(c1cccnc1NCc1ccncc1)Nc1ccc2c(c1)NCC2(C)C
InChI InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28)
InChI Key RAHBGWKEPAQNFF-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Motesanib has undergone many clinical trials to determine its potential as a cancer therapy. It progressed to Phase 3 evaluation in NSCLC but these studies were terminated as they failed to meet the predetermined primary endpoint. Click here to link to ClinicalTrials.gov's full list of motesanib trials.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Inhibitis vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis and may therefore reduce the vascularisation which underpins and supports tumour development and growth.